Company Overview and News

 
Deccan Cements Limited - Changes in Shareholding

2018-03-13 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
News Live: SFIO summons Chanda Kochhar, Shikha Sharma in PNB fraud case

2018-03-06 moneycontrol
Serious Fraud Investigation Office (SFIO) summons ICICI Bank Managing Director and CEO Chanda Kochhar and Axis Bank MD Shikha Sharma in the Rs 12,700 crore Punjab National Bank fraud case, reports CNN-News18.

 
News Live: NPP president Conrad Sangma sworn in as Meghalaya Chief Minister

2018-03-06 moneycontrol
The Central Bureau of Investigation has detained Vipul Chitalia, Vice President (Banking Operations) of Gitanjali Group, in Mumbai in the Rs 12,700 crore Punjab National Bank fraud case, reports PTI.

 
News Live: 10 stocks saw MFs raise stakes for 8 quarters in a row, deliver 200% returns

2018-03-06 moneycontrol
Mutual funds have raised their stakes in at least 10 small and midcap stocks for eight consecutive quarters on the trot, data compiled from database Capitaline showed. The stocks have risen up to 200% during the said period. These include Tata Chemicals, India Cements, Carborundum Universal, Oriental Carbon Chemicals, JK Cements, Deccan Cements, VST Industries, GHCL, Symphony and Entertainment Network.

 
Deccan Cements Limited - Financial Result Updates

2018-02-09 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
 
Deccan Cements Limited - Financial Result Updates

2017-11-10 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
 
Deccan Cements Limited - Updates

2017-09-14 feedproxy.google
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Broker's call: Deccan Cements (Buy)

2017-08-11 thehindubusinessline
Deccan Cements Ltd (DCL) was promoted and incorporated as a public limited company in the year 1979 by a technocrat entrepreneur MB Raju, who is also its current Executive Chairman. DCL has a very strong network of more than 1,000 cement dealers and consignment agents spread through out the length and breadth of Andhra Pradesh and Telangana and also, in the other southern States of Tamil Nadu, Karnataka and Kerala as well as the neighbouring States namely Maharashtra, Madhya Pradesh, Chattisgarh and Odisha.

 
Deccan Cements Limited - Results

2017-07-25 feedproxy.google

 
 
Stock split momentum yet to catch up with the bull run

2017-05-26 thehindubusinessline
Generally when markets peak, stock splits by companies gather momentum. The aim is to make the shares affordable to investors and create more liquidity. However, this time the scenario has been different so far.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...